Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.

ABSTRACT:

Background

The gene EZH2, the polycomb group protein enhancer of zeste 2, encodes a transcriptional repressor that also serves as a histone methyltransferase that is associated with progression to more advanced disease in a variety of malignancies. EZH2 expression level in urothelial cell carcinoma (UCC) is highly correlated with tumor aggressiveness, but it has not been determined if specific EZH2 genetic variants are associated with UCC risk. This study investigated the potential associations of EZH2 single-nucleotide polymorphisms with UCC susceptibility and its clinicopathologic characteristics.

Methodology/principal findings

A total of 233 UCC patients and 552 cancer-free controls, all of whom were from Taiwan, were analyzed for four EZH2 single-nucleotide polymorphisms

SUBMITTER: Yu YL 

PROVIDER: S-EPMC3972169 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature